Subject Index

A
actinomycin
in immunosuppression, 431
acute rejection
biopsies of, 387
aldosterone, plasma
during haemodialysis in terminal renal failure, 332–41
allograft rejection
renal, 464–70
urinary fibrinogen degradation products and, 500–7
allografts
glomerular basement membrane in long-term, 399–405
allotransplant disease
399–405
alumina
as absorbent of low molecular weight substances, 300
amino acids
abnormal metabolism of, in uraemia, 152–8
ammonia concentration
with oxystarch treatment, 148
ammonia binding capacity
of oxystarch, 143–50
amyloidosis
biopsies, 384
anaemia, uraemic
histidine supplements in treatment of, 160–5
aneptic patients
treatment with vitamin D for osteodystrophy, 217
angiotensin
baroreceptor activity and responsiveness to, in chronic renal failure, 540–4
antibody-mediated cell-dependent immune lympholysis
456
anticoagulant therapy
and glomerulonephritis, 65–8, 74, 78–9, 81
antigen studies
blood group, 282, 285
artery grafts
bovine carotid as blood access devices, 229–35
artificial kidney system
portable, with absorbents, 298–305
audio-visual teaching programme
for home dialysis patients, 538–9
Australia antigen
correlation between liver function abnormalities and presence of, 498
Australia antigaenaemia
incidence after transplantation, 437
A-V fistula puncture
new needle for, 553–5
A-V shunts
for haemodialysis in children, 511–15
for long-term hyperalimentation in non-uraemic patients, 516–21
azathioprine
in immunosuppression, 431
B
babies
haemodialysis of premature and newborn, 349–62
baroreflex sensitivity
in chronic renal failure, 540–4
Belzer's plasma
54
biochemical results
in dialysis of infants, 356–7
blood access
for chronic infant haemodialysis, 350
blood group antigen studies
282, 285
blood level of middle molecular substances
during uraemia and haemodialysis, 263–70
blood lines
dialysis, 350, 352
blood transfusion
graft survival in relation to, xliv paediatric, lxxvi–lxxix responsiveness to HL-A by monitoring, 471–4
bone disease, renal
91–122
preventive therapy, 91–2
preventive therapy under maintenance dialysis, 95–122
bone histology, quantitative
in acute renal failure, 316–23
bone lesions
effects of diet, dialysis and transplantation on in chronic uraemia, 325–31
bovine carotid artery grafts
as blood access devices, 229–35
Brunius and Gelin technique of preserving kidney
480
BSP retention
after transplantation, 437
C
cadaver transplants
xl–xliv
calcification
metastatic and vitamin D therapy, 224
calcium loss in renal osteodystrophy
measurement by neutron activation analysis, 173–81
capillary agglutination test
455
carotid artery grafts
bovine, as blood access devices, 229–35
bovine, survival rates, 232–3
surgical technique, 229–31

catheter failure
in peritoneal dialysis, 366–7

cerebral death
assessment of antecedent conditions, 21–3
assessment of cerebral state, 23–8
diagnosis of, 20–28

charcoal
as absorbent of low molecular weight substances, 300

children
blood transfusions, lxvi–lxix
causes of death on haemodialysis, lxxiv–lxxv
causes of graft failure in, lxxvii–lxxviii
congenital hypoplasia in, lxxii
glomerulonephritis in, lxx
haemodialysis of premature and newborn babies, 349–62
hepatitis in, lxxvi–lxxix
home dialysis of, lxxix
incidence of hereditary chronic nephritis in, lxxi
incidence of nephrectomy in, lxxvi
on maintenance haemodialysis, renal osteodystrophy in, 197–201
on RDT in Europe, lxvi–lxxi
RDT after transplantation, lxiv–lxxiii
rehabilitation, lxxvi
tissue typing and graft survival, lxxv–lxvii

chronic infant haemodialysis
blood access for, 350

chronic rejection
biopsies, 388

clearance values
in peritoneal dialysis, 250–1

clinical criteria
in acute glomerulonephritis, 375

clinical features
in acute glomerulonephritis, 376–7

corticosteroids
and glomerulonephritis, 69–70, 71, 82

cuprophan membranes
236, 306

D

dearth
causes of on haemodialysis, lxxiv–lxxv
diagnosis of cerebral, 20–8
transplantation and, xxxiv–xxxvi

dearth, cerebral
assessment of antecedent condition, 21–3
assessment of cerebral state, 23–8

Dextran 40 solution
for kidney preservation, 480

diabetes
and renal allograft rejection, 468

dialysate
in infant dialysis, 353
small supply system, 298–305
calcium levels in management of bone disease, 95–6
recirculating system, 237–8

dialysers
Belzer, 53
coil, 332, 352
Cordis Dow, 332, 525, 526
current, 522–7
Dasco SP 75, 272
EX-93, 306
Gambro, 53
Gambro-Alwall, 306, 312
Gambro-Lundia, 272, 291, 306
Kii, 253, 254, 298, 299, 523
Meltec, 526
middle molecule clearance in current, 522–7
Mini-D, 352
Model 3 Dow HFAK, 253
multiple point support Kii, 526
paediatric, 332
parallel flow, 352
portable, 298–305
Rhône-Poulenc, 306
RP 1D, 237
Trenvelon UF 1.5, 272, 274
Trenvelon UF 100, 306
UF 2, 272
UF 100, 272

dialysis
bovine carotid artery grafts as blood access devices, 229–35
complications of in infants, 367–8
effect of on bone lesions in chronic uraemia, 326–31
effect of on growth and development in children, 358–9
frequency of, 345
one year follow up short with membrane highly permeable to middle molecules, 236–46
peritoneal, bi-directional permeability of, 247–62
portable, with absorbents, 298–305
preventive therapy for bone disease under maintenance, 95–122
procedures with infants, 353–4
survival rates of infants under, 255–6
thrombus formation on membranes, 306–15
training for self, 343

dialysis cycle
model of mass transfer during dwell period of peritoneal, 258–61

dialysis membranes
role of support system in genesis of thrombus formation on, 306–15


dialysis schedule
and peripheral neuropathy, 271–81


dialysis unit
intensive utilization of, 342–8


diet
effect of on bone lesions in chronic uraemia, 325–31

diffuse sclerosing glomerulonephritis
biopsies, 385

1, 25 dihydroxycholecalciferol
in chronic renal failure, 202–8
in normal and uraemic man, 210–16
direct cell mediated lympholysis
456–7
diuresis
effect of isoproterenol on water, 422–6
dog kidney
hyperbaric hypothermic perfusion pre-
servation of ischaemically damaged, 479–85
drugs
immunosuppressive, 431

E
ECIB
in immunosuppression, 431
eflux measurements
in peritoneal dialysis, 249–50
effusion
intractable uraemic pericardial, 289–97
electrocardiography
Hewlett Packard 1510A, 274
electromicroscopy
for haematuria, 393
micro-perfusion-fixed studies of nephrons
by, 551–2
of the basement membrane, 400
embolisation
after carotid artery graft, 231
eythropoiesis
in uraemia, 129–30
extracapillary glomerulonephritis
biopsies, 384
exudative glomerulonephritis
biopsies, 384–5

F
feeding
of infants under dialysis, 355
fibrin deposition
63–5, 74
fibroblasts
blocking of, 457
killer activity against panel, 457
fistula
for haemodialysis in children, 511–15
retrograde arteriovenous forearm, 528–30
fistula puncture
A-V, new needle for, 553–5
focal proliferative glomerulonephritis
biopsies, 386
foetal development
in experimental uraemia, 127–35

G
Gelin solution
55
glomerular basement membrane
in long-term allografts with heavy pro-
teinuria, 399–405
glomerulonephritis
57–88
acute, serial renal biopsies for, 378
anticoagulant treatment, 65–8, 74, 78–9
biopsies, 384, 385, 386
chronic, and uraemic pericardial effusion,
290, 291
clinopathological correlations in acute,
375–81
course and therapy, 69–88
exudative, 377
in children, lxii
non-exudative, 378
serum and urine fibrin degradation products
and complement in, 531–7
urinary fibrinogen degradation products
and, 500–7
graft
bovine carotid artery as blood access
devices, 229–35
graft failure
causes of, xxxii–xxxiii
causes of in children, lxxiii–lxxiv
graft survival
in relation to pregnancy and blood
transfusion, xlii–xliv
tissue typing and, xxxvi–xlv
graft tolerance
after withdrawal of azathioprine, 437

H
haematuria
of renal parenchymal origin in adults with
normal function, 391–8
haemodialysis
at constant plasma sodium concentration,
335–7
at constant plasma potassium concentra-
tion, 337
blood access for chronic infant, 350
blood level of middle molecular substances
during, 263–70
calcium balances under, 96
children on, causes of death, lxxiv–lxxv
in neonates, infants and small children,
A-V shunts and fistulae for, 511–15
in terminal renal failure, plasma aldo-
sterone during, 332–41
of premature and newborn babies, 349–62
preventive therapy for, 94
renal osteodystrophy in children on main-
tenance, 197–201
renal osteodystrophy in patients on,
187–96
haemodialysis, chronic
peripheral neuropathy and, 271–81
reproductive potential in males treated by,
282–7
haemodialysis patients
radiographic changes of renal osteodys-
trophy in, 182–6
haemoglobin levels
in dialysed infants, 358
heparin
and glomerulonephritis, 70, 73, 75, 77–8,
79–81, 82
hepatic dysfunction
after transplantation, 437–9
hepatic failure
evolution and prognosis in transplant
patients, 435
in transplant patients, 435–7

561
hepatitis
in children, lxxxvi–lxxxix
RDT and transplantation, xlvi–l

histidine supplements
in treatment of uraemic anaemia, 160–5

HL-A antigen
in kidney tissue, 406–11
responsiveness to, 471–4

home dialysis
343
audio-visual teaching programme for
training in, 538–9
children on, lx, lxi, lxxxix
patients related to population, li–lvi
training, video box colour film for, 545–6

homotransplant rejection
urinary fibrinogen degradation products
and, 500–7

hormone
the natriuretic, 3–16

hyperacute rejection
biopsies of, 387

hyperalimentation, long-term
A-V shunt for non-uraemic patients,
516–21

hypercalcaemia
and vitamin D therapy, 224–5

hyperparathyroidism
defective vitamin D metabolism, 93–4
phosphate retention in, 92–3

hyperplasia
congenital, in children, lxii

hydroxyproline, plasma
in renal osteodystrophy, 187–96

ice storage of dog kidney
479

immunity
comparison of humoral with CMI, 461
humoral and cell-mediated, in transfused
uraemics, 455–63

immunofluorescence
for haematuria, 393
in kidney biopsies, 382–3
in renal biopsies, 61–3
technique for localisation of HL-A
antigens in kidney tissue, 406–11

immunohistology
combined with phase-contrast microscopy
for evaluation of kidney biopsies,
382–90

immunosuppression
in renal transplantation, malignant
tumours following, 429–33

immunosuppressive drugs
431
infants
A-V shunts and fistulae for, 511–15
blood access in acute and chronic cases,
356
infection
soft tissue, after carotid artery graft, 231
influx measurements
in peritoneal dialysis, 250

intestinal tract
increased nitrogen removal from in
uræmia, 143–50

intracellular type solution
storage of kidneys in, 487–92

intrarenal uraemic pericardial effusion
289–97

intrarenal haemodynamics
determination of by 133Xenon during
hypothermic perfusion of human
cadaver kidneys, 493–9

isoproterenol
effect of on water diuresis, 422–6

jaundice
in transplanted patients, 435

kidney
dog, preservation of ischaemically dam-
aged, 479–85
donors, 32–9
long-term evaluation of functional and
histological status of stored, 487–92
normal, biopsies of, 384
preparation and pre-treatment of, 39–42

kidney biopsies
immunohistology combined with phase-
contrast microscopy for evaluation of,
382–90

kidney tissue
HL-A antigens in, 406–11

kidney transplants
late failures in, 399–405
responsiveness to HL-A and, 471–4

Lasix
54

leucoagglutination test
456

leucocyte culture
mixed, 464–70

leucocyte reaction
inhibition of unidirectional mixed, 456

light microscopy
for haematuria, 392–3
in evaluation kidney biopsies, 382
in glomerulonephritis, 69
micro-perfusion-fixed studies of nephrons,
551–2

liver
pathology of in transplanted patients,
435–6

liver disease
in transplanted patients, 434–45

liver function abnormalities
correlation between Au antigen and, 438
evolution of, 438–9

livedo reticularis
pharmacodynamics of in renal failure,
547–50

lobular glomerulonephritis
biopsies, 385–6
lymphocytotoxicity test 455
lympholysis
antibody-mediated cell-dependent immune, 456
direct cell mediated, 456–7

M
membrane
cellular deposits on, 312
cuprophan, 236, 306
RF polyacrylonitrile, 236
short dialysis with highly permeable to middle molecules, 236–46
membrane support system
role of in genesis of thrombus formation, 306–15
membrano-proliferative glomerulonephritis
biopsies, 385
membranous glomerulonephritis
biopsies, 386
metabolism, abnormal
of amino acids in uraemia, 152–8
methylprednisolone
in pericardiocentesis, 290, 292
microscopy
light, 69, 382, 392–3, 551–2
phase-contrast, 382
middle molecular substances
blood level of during uraemia and haemodialysis, 263–70
middle molecule hypothesis
255–6
middle molecules
bi-directional permeability of the human peritoneum to, 247–62
clearances in current dialysis, 522–7
membrane highly permeable to, 236–46
removal of in peritoneal dialysis, 253–5
migratory inhibitory factor
blockade of release of, 406
detection of, 456
monitoring equipment
for infant dialysis, 355
monoamine oxidase
and noradrenaline, 168
motor nerve conduction velocity
in haemodialysis, 274, 276–8

N
necrotising glomerulonephritis
biopsies, 384
neonates
A-V shunts and fistulae for, 511–15
nephrectomy
incidence in children, lxvi
total, xlv
nephritis
hereditary chronic in children, lxii
nephrons
identification of individual, 551–2
neuropathy
biopsies, 386
nephrosclerosis
biopsies, 384
nephrotic syndromes
proximal tubular reabsorption and sodium retention in, 412–21
neurological tests
274, 275
neuropathy, peripheral
dialysis schedule and, 271–81
neutron activation analysis
calcium loss in renal osteodystrophy as measured by, 173–81
nitrogen, faecal
effects of oxystarch on, in uraemia, 136–42
nitrogen excretion
with oxystarch treatment, 147–8
nitrogen removal
increased from the intestinal tract in uraemia, 143–50
noradrenaline
depletion in uraemia, 166–8

O
organ procurement
31–50
osteodystrophy
effects of transplantation on renal, 446–54
in acute renal failure, 376
of dialysed patients treated with vitamin D, 217–25
osteodystrophy, renal
calcium loss in, 173–81
in children on maintenance haemodialysis, 197–201
plasma hydroxyproline in, 187–96
radiographic changes in haemodialysis patients, 182–6
oxystarch
ammonia binding capacity and nitrogen removal, 143–50
effects of on blood and faecal nitrogen in uraemia, 136–42

P
paediatric dialysers
352
parathyroidectomy
and plasma hydroxyproline, 193–6
pathological criteria in acute glomerulonephritis
375
pathological features in acute glomerulonephritis
377–8
patients
audio-visual teaching programme for training in home dialysis, 538–9
haemodialysis, and plasma hydroxyproline, 188–91
humoral and cell-mediated immunity in transfused, 455–63
liver disease in transplanted, 434–45
non-dialysed and plasma hydroxyproline, 191–3
non-uraemic, A-V shunt for long-term hyperalimentation in, 516–21
osteodystrophy of dialysed treated with vitamin D, 217–25
selection of for study of bi-directional permeability of peritoneal dialysis, 249
training for self-dialysis, 343, 344
with controllable hypertension, haemodialysis and, 333–5
with normal blood pressure, haemodialysis and, 333
with terminal renal failure, plasma aldosterone during haemodialysis, 332–41
with uncontrollable hypertension, haemodialysis and, 333–7
perfusion
continuous, 48–51
of human cadaver kidneys, 493–9
pericardial effusion
intractable uraemic, 289–97
pericardiocentesis, 289, 290, 291–2
pericarditis
steroid therapy, 292, 295
peritoneal dialysis
bi-directional permeability to middle molecules, 247–62
children on, 1xi
chronic, 363–71
model of mass transfer during dwell period of cycle, 258–61
peritoneum
bi-directional permeability of human to middle molecules, 247–62
middle molecule mass-transfer properties of, 253
peritonitis
in peritoneal dialysis, 368–9
permeability area
computer solution for, 260–1
mathematical model for determination of, 258–61
pharmacodynamics
of lividomycin in renal failure, 547–50
phase-contrast microscopy
with immunohistology for evaluation of kidney biopsies, 382–90
phosphate
restriction of in bone disease, 95
distal reabsorption of in nephrotic syndrome, 417, 419
phosphate retention
avoidance of in renal bone disease, 94
in hyperparathyroidism, 92–3
plasma aldosterone
during haemodialysis in terminal renal failure, 332–41
plasma hydroxyproline
in renal osteodystrophy, 187–96
platelets
adherence to dialysis membranes, 307, 309
polyneuropathy
in chronic renal failure, 166
prednisolone
in immunosuppression, 431
pregnancy
graft survival in relation to, xlii–xlv
preservation
of ischaemically damaged dog kidney, 479–85
pre-transplant transfusion
464–70
proliferative glomerulonephritis
biopsies, 384–5
pyelonephritis
biopsies, 384
chronic, and uraemic pericardial effusion, 289–90
radiographic changes
of renal osteodystrophy in haemodialysis patients, 182–6
reabsorption
proximal tubular, in nephrotic syndromes, 412–21
recirculating system
of RP 1D dialysers, 237–8
regular dialysis treatment
and patients with terminal renal failure, 332–41
death, causes of, xxxiii–xxxvi
duration of, xxiv–xxvi
sex distribution, xxii–xxiv
rehabilitation
xliv–xlvi
and home dialysis, 345
of paediatric patients, lxxvi
renal biopsy
for haematuria, 392, 393
renal bone disease
91–122
preventive therapy, 91–2
preventive therapy under maintenance dialysis, 95–122
renal disease
primary, xxi
renal failure
acute quantitative bone histology in, 316–23
chronic, baroreceptor activity and responsiveness to angiotensin in, 540–4
chronic, 1,25 dihydroxycholecalciferol in, 202–8
pharmacodynamics of lividomycin in, 547–59
renal function
in uraemia, 130–4
renal osteodystrophy
101–3
calcium lost in, as measured by neutron activation analysis, 173–81
in children on maintenance haemodialysis, 197–201
plasma hydroxyproline in, 187–96
radiographic change of in haemodialysis patients, 182–6
renal transplantation
effects on renal osteodystrophy, 446–54
malignant tumours following immunosuppression in, 429–33
preservation of kidney, 42–56
rejection
renal allograft, 464–70
transplant biopsies, 387–8

reproduction potential
in males treated by chronic haemodialysis, 282–7

Resonium-A
339

S

sclerosing glomerulonephritis
biopsies, 386

self dialysis
343: 344, 345–6

serum degradation products
and complement in glomerulonephritis, 531–7

serum glutamic pyruvic transaminase
after transplantation, 437–8

serum protein levels
in dialysed infants, 358

semen studies
282–3, 285–6

skeletal development
in uraemia, 128–9

sodium secretion
control of, 3–16

sodium retention
in nephrotic syndrome, 412–21

survival rates
of children after transplantation, bxiv–lxxiii

sympathicopathies
toxic, in uraemia, 166–9

T

thrombosis
after carotid artery graft, 231–2

thrombus formation
role of membrane support system in genesis of, on dialysis membranes, 306–15

tissue typing
graft survival and, xxxvi–xlv
in children, lxxv–lxxvi

transplant kidneys
biopsies, 387

transplant rejection
biopsies, 387–8

transplantation
and RDT, xxvi–xxxii
children after, bxiv–lxxiii

effect of on bone lesions in chronic uraemia, 326–31

hypothermic perfusion of human cadaver kidneys, 493–9

renal, effects of on osteodystrophy, 446–54

storage of kidneys in intracellular solution, 487–92

transplants
cadaver, xl–xliv
living donor, xxxvii–xl
pediatric, lxi–lxii

triaminolone hexacetinide
in percutaneous biopsy, 289, 290

tumours
malignant following immunosuppression in renal transplantation, 429–33

tyrosine hydroxylase
and noradrenaline, 168

U

ultrafiltration rates
in peritoneal dialysis, 250

uraemia
abnormal metabolism of amino acids in, 152–8

blood level of middle molecular substances during, 263–70

chronic, effects of diet, dialysis and transplantation on bone lesions, 325–31

1,25 dihydroxycholecalciferol in, 210–16

effects of oxystarch on blood and faecal nitrogen in, 136–42

foetal development in experimental, 127–35

increased nitrogen removal from the intestinal tract, 143–50

noradrenaline depletion in, 166–8

toxic sympathicopathies in, 166–9

uraemic anaemia
histidine supplements in treatment of, 160–5

uraemic osteodystrophy
316–23

uraemics
humoral and cell-mediated immunity in transfused, 455–63

urea nitrogen appearance and balance
and oxystarch, 145–7

urinary fibrinogen degradation products
and renal homotransplant rejection, 500–7

urine fibrin degradation products
and complement in glomerulonephritis, 531–7

V

velocities
motor nerve conduction, 274, 276–8

Vickers hyperbaric perfusion apparatus
480

video box colour film
for home dialysis training, 545–6

vitamin D
osteodystrophy of dialysed patients treated with, 217–25

vitamin D metabolism
defective in hyperparathyroidism, 93–4

vitamin D therapy
in renal bone disease, 94–5

W

water contaminants
in renal bone disease, 96

water diuresis
effect of isoproterenol on, 422–6

weighing procedures
with infants under dialysis, 355